CA
SUPN icon

Continuum Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Continuum Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed -$615 – 1911
2024
Q4 		$615 Hold
17
– – ﹤0.01% 1703
2024
Q3 		$615 Buy
+17
New +$531 ﹤0.01% 1739

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Continuum Advisory's SUPN Position: Q1 2025 in Review

Continuum Advisory sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 17 shares — an estimated $615 sold.

Continuum Advisory first reported a position in SUPN in Q3 2024 and held it in 2 quarters. The position peaked at $615 in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Continuum Advisory reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 17 Supernus Pharmaceuticals shares in Q1 2025, an estimated $615.
  • Continuum Advisory first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Continuum Advisory's Supernus Pharmaceuticals position peaked at $615 in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.